Literature DB >> 15249587

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.

Paul Richardson, Kenneth Anderson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15249587     DOI： 10.1200/JCO.2004.05.984

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

Review 1.  Autologous stem cell transplantation in hematological malignancies.

Authors:  Norbert-Claude Gorin
Journal:  Springer Semin Immunopathol       Date:  2004-10-07

Review 2.  Treatment of relapsed and refractory myeloma.

Authors:  Jonathan Kaufman; Charise Gleason; Sagar Lonial
Journal:  Curr Hematol Malig Rep       Date:  2009-04       Impact factor: 3.952

Review 3.  The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective.

Authors:  Jonathan L Finlay; Stergios Zacharoulis
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

Review 4.  Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Authors:  Farrukh T Awan; Amy J Johnson; Rosa Lapalombella; Weihong Hu; Margaret Lucas; Beth Fischer; John C Byrd
Journal:  Leuk Lymphoma       Date:  2010-01

5.  Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

Authors:  Jessie-F Fecteau; Laura G Corral; Emanuela M Ghia; Svetlana Gaidarova; Diahnn Futalan; Ila Sri Bharati; Brian Cathers; Maria Schwaederlé; Bing Cui; Antonia Lopez-Girona; Davorka Messmer; Thomas J Kipps
Journal:  Blood       Date:  2014-07-02       Impact factor: 22.113

Review 6.  Lenalidomide in myelodysplastic syndrome and multiple myeloma.

Authors:  Sachin R Shah; Thu M Tran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

8.  Front line treatment of elderly multiple myeloma in the era of novel agents.

Authors:  Marie-Dominique Venon; Aldo M Roccaro; Julie Gay; Anne-Sophie Moreau; Remy Dulery; Thierry Facon; Irene M Ghobrial; Xavier Leleu
Journal:  Biologics       Date:  2009-07-13

9.  Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma.

Authors:  Ibrahim A Darwish; Nourh Z Alzoman; Reem M Abuhejail; Tilal E El-Samani
Journal:  Chem Cent J       Date:  2012-10-26       Impact factor: 4.215

10.  A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine.

Authors:  Ibrahim A Darwish; Nasr Y Khalil; Ahmed H Bakheit; Nourh Z Alzoman
Journal:  Chem Cent J       Date:  2012-10-16       Impact factor: 4.215
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.